Navigation Links
IMD Announces 35% Increase in Revenues for OMI
Date:8/2/2011

TAMPA, Fla., Aug. 2, 2011 /PRNewswire/ -- IMD Companies Inc. announces that when it files its Second Quarter Financial Reports with OTC Markets, LLC, the reports will reflect a 35% increase in revenues for Integrated Medical Diagnostics (Integrated) and Optimum Mobile Imaging (OMI) bringing the year to date revenues of the subsidiaries to $149,839. Both Integrated and OMI are wholly owned subsidiaries that were purchased by IMD last year to operate the company's diagnostic testing business.  Testing operations continue to be performed in several states with OMI mainly concentrated in Arizona, but the companies are working on expanding testing into new markets in the near future.  The primary service offered by Integrated is the PCI Heartscan®, which concentrates on the early detection of Cardio Vascular disease and describes blockage in the carotid arteries, while OMI provides mobile imaging services in several modalities to the medical community. The company will file its complete financial reports this month.

"As promised in our open letter to shareholders, the company continues to expand operations and achieve revenue growth in its diagnostic testing arena," stated IMD CEO Saeb Jannoun. "We have been able to create this growth in testing while remaining focused on expansion into the disease prevention and weight-loss industries," Jannoun concluded.  Earlier this year IMD announced the acquisition of Positive Solutions Centers, LLC. as a subsidiary to develop and grow their juvenile weight-loss business.

ABOUT IMD COMPANIES, INC.

IMD Companies, Inc., (OTC MARKETS: ICBU) is a Florida corporation, engaged in the medical diagnostics and health and fitness industries. Its primary products and services lie in the health and fitness nutraceutical and medical diagnostics services markets. The company further plans to expand into the weight-loss industry.

The company delivers its medical diagnostic services on-site participating medical clinics and physician offices. The nutraceutical supplements, pills, bar and gels will be marketed and distributed through participating clinics and on-line web marketing retail methods.  The company will continue to develop its innovative marketing strategies, including the use of social networking vehicles.


Safe Harbor Statement:

Certain statements made in this press release constitute forward-looking statements that are based on management's expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. All forward-looking statements speak only as of the date of this press release and the company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

www.imdcompanies.com


'/>"/>
SOURCE IMD Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to a new market research report ... Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, Passive), ... expected to reach USD 1,519.2 Million by 2021 from USD 856.3 Million ... Continue Reading ... ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, Inc. ... biology company focused on delivering scientific and medical ... that Chairman and Chief Executive Officer Keith ... on Wednesday, December 14, 2016 at 1:00 p.m. ... are not yet familiar with the Company, an ...
(Date:12/7/2016)... December 7, 2016 According to ... titled , Global Market Study on Multiplex Detection Immunoassay: North ... , the global multiplex detection immunoassay market is expected to witness ... ... ,      (Logo: ...
Breaking Medicine Technology:
(Date:12/7/2016)... Chicago, IL (PRWEB) , ... December 07, 2016 , ... ... giving back this holiday season by donating a portion of proceeds to two local ... North Chicago Animal Control & Friends is a team of authorized and ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... a 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. ... Awards recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows ... that follows. , “Fred Rides a Train” is the creation of published author, ... since her teen years in Michigan. The "Fred, the Dog" series is her first ...
Breaking Medicine News(10 mins):